Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Cellectar Biosciences, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 21 | 20 | −1 |
| Shares | 296.2K | 346.8K | +50.7K (+17.1%) |
| Value | $1.65M | $1.04M | −$607.8K (−36.8%) |
New holders (4)
Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Warberg Asset Management LLC | 13,900 | $41.0K | 0.01% |
| XTX Topco Ltd | 12,243 | $36.1K | 0.00% |
| Susquehanna International Group, LLP | 12,204 | $36.0K | 0.00% |
| TD Waterhouse Canada Inc. | 63 | $181 | 0.00% |
Sold out (5)
Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Renaissance Technologies LLC | 24,900 | $139.4K |
| Citadel Advisors LLC | 18,526 | $103.7K |
| Dimensional Fund Advisors LP | 13,033 | $73.0K |
| Group One Trading, L.P. | 23 | $129 |
| Citigroup Inc | 19 | $106 |